Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22481134 | 1.00 | ADRB1 (0.56) | ADRB1HIF1ALMNACYP2D6CYP2C9 | |
| SCHEMBL22480828 | 0.97 | ADRB1 (0.56) | ADRB1HIF1ALMNACYP2D6CYP2C9 | |
| SCHEMBL22481279 | 0.95 | ADRB1 (0.59) | ADRB1HIF1ALMNACYP2D6CYP2C9 | |
| SCHEMBL22481091 | 0.89 | ADRB1 (0.53) | ADRB1HIF1ALMNACYP2D6HTR1A | |
| SCHEMBL22481318 | 0.89 | ADRB1 (0.53) | ADRB1HIF1ALMNACYP2D6HTR1A | |
| SCHEMBL22481314 | 0.82 | ADRB1 (0.54) | ADRB1HIF1ALMNACYP2D6CYP2C9 | |
| SCHEMBL22481296 | 0.82 | ADRB1 (0.54) | ADRB1HIF1ALMNACYP2D6CYP2C9 | |
| SCHEMBL22481051 | 0.80 | TSHR (0.41) | ADRB1HIF1ALMNACYP2D6CYP1A2 | |
| SCHEMBL22481122 | 0.80 | ADRB1 (0.54) | ADRB1HIF1ALMNACYP2D6CYP2C9 | |
| SCHEMBL22481295 | 0.80 | ADRB1 (0.54) | ADRB1HIF1ALMNACYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263749-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263749-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230157974-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230157974-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20220169612-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2021-12-02 | — | — | US | disclosed |
| US-11040944-B2 | Beta adrenergic agonist and methods of using the same | CURASEN THERAPEUTICS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-10947196-B2 | Beta adrenergic agonist and methods of using the same | CURASEN THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200308115-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
| US-20200308114-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308114-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | ADRB1 2/4885HIF1A 2371/4885LMNA 1389/4885 |
| US-20200308115-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | ADRB1 2/4885HIF1A 2371/4885LMNA 1389/4885 |
| US-10947196-B2 | Beta adrenergic agonist and methods of using the same | ADRB2, ADRB1, ADRA2C | ADRB1 2/4885HIF1A 2371/4885LMNA 1389/4885 |
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | ADRB1 2/4885HIF1A 2371/4885LMNA 1389/4885 |
| US-11040944-B2 | Beta adrenergic agonist and methods of using the same | ADRB2, ADRB1, ADRA2C | ADRB1 2/4885HIF1A 2371/4885LMNA 1389/4885 |
| US-20220169612-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRA2B, ADRB2, ADRB1 | ADRB1 3/4885HIF1A 3024/4885LMNA 764/4885 |
| US-20230263749-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | ADRA2A, SNCA, ADRA1A | ADRB1 5/4885HIF1A 701/4885LMNA 228/4885 |
| US-20230157974-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | ADRA2A, SNCA, ADRA1A | ADRB1 5/4885HIF1A 701/4885LMNA 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.